Mutation in superoxide dismutase 1 (SODI), a Cu/Zn enzyme that removes oxygen radicals and protects against oxidative injury, has been implicated in some cases of familial amyotrophic lateral sclerosis (FALS). As a first approach to examining the mechanism(s) through which these mutations cause specific degeneration ofmotor neurons, we have used immunocytochemistry to identify the distribution of SODI in populations of cells in the peripheral and central nervous systems. In (02), yielding H202 and 02; subsequent removal of H202 is facilitated by catalase and glutathione peroxidase (2). Thus, SOD activity can protect against oxidative stress produced by oxygen radicals and may represent a first line of defense against oxidative damage mediated by oxygen radicals (1, 2).
nosa. In motor neurons, SODI immunoreactivity was abundant in perikarya, dendrites, and axons; most ofthis activity appeared to be free in the cytoplasm, although a portion was associated with membranous vesicles, presumably peroxisomes. Since a variety of central nervous system neurons, including pyramidal cells in cerebral cortex and neurons of the CA3 and CA4 sectors of the hippocampus, showed high immunoreactivity but are unaffected in ALS, the apparent abundance of SOD1 does not predict vulnerability of neurons to mutations in SOD1. Rather, SOD1 accumulates in many neuronal populations but is particularly abundant in motor neurons. Consistentwith recent studies of FALS-linked SOD1 mutations in vitro and in transgenic mice, our findings offer further support for the view that the mutations confer a gain of adverse function. In this view, high, rather than limiting, levels of SOD1 may place motor neurons selectively at risk in FALS.
Part of the free-radical scavenger system, superoxide dismutases (SODs; EC 1.15.1.1) include SOD1, a cystosolic Cu/Zn enzyme; SOD2, a Mn-containing mitochondrial matrix SOD; and SOD3, an extracellular form of Cu/Zn SOD (1) . These metalloenzymes catalyze the dismutation of superoxide anions (02), yielding H202 and 02; subsequent removal of H202 is facilitated by catalase and glutathione peroxidase (2) . Thus, SOD activity can protect against oxidative stress produced by oxygen radicals and may represent a first line of defense against oxidative damage mediated by oxygen radicals (1, 2) .
SODs are present in the central and peripheral nervous systems, but the cellular and intracellular distributions of SOD1 in neuronal populations are not well defined. Biochemical assays of SOD1 activity have not localized enzymatic activities to specific cells in the brain (3, 4) , and in situ hybridization and immunocytochemical studies have focused only on selected areas of the nervous system in either control (5) (6) (7) (8) or diseased (9, 10) brain.
It has been hypothesized that alterations in antioxidant systems, including SOD1, are implicated in neurodegenerative diseases (5, (11) (12) (13) (14) (15) . In some cases of familial amyotrophic lateral sclerosis (FALS), mutations in SOD1 have been linked to disease (16) (17) (18) , and at least two of these mutations can cause motor neuron disease when expressed in transgenic mice (ref. 19; unpublished observations). However, the mechanism(s) responsible for selective vulnerability to degeneration of motor neurons in FALS-linked SOD1 mutations is unknown. To identify events that lead to motor neuron death, it is critical to define the cellular distributions of SOD1 in the peripheral and central nervous systems. To this end, we have used protein blotting and immunocytochemistry at both light and electron microscopic levels to localize SOD1 in the mouse, nonhuman primate, and human nervous systems.
MATERIALS AND METHODS
Generation and Characterization ofanti-SODI Antibody. A pentadecapeptide (CYDDLGDGGNEESTK) of which the C-terminal 13 amino acids correspond to residues 125-137 of mouse and human SOD1 was crosslinked to keyhole limpet hemocyanin (Pierce), emulsified in Freund's adjuvant, and used to immunize rabbits, as described (20 (23) (24) (25) . One rabbit produced a high-titer response. After affinity purification, this antibody (pAb-m/h-SOD1) revealed strong immunoreactivity with, and specificity for, the 16-kDa mouse SOD1 polypeptide on immunoblots of whole cell extracts of the mouse neuroblastoma N2a cell line (Fig. 1B, Fig. 2A and C) and human ( Fig. 2 D-F ).
This staining was specific, since preincubation of the antibody with the immunizing peptide (100 p,g/ml) completely eliminated reactivity (Fig. 2B) (denoted by the asterisk in Fig. 2A ), as well as motor neuron terminals in striated muscle (data not shown). These observations indicate that SOD1 is also present in terminals of some axons. Both motor and sensory cranial nuclei in the brainstem showed marked SOD1 immunoreactivity, with particular abundance in the nuclei of the III, V, VII, VIII, and IX cranial nerves. Dorsal root (data not shown) and trigeminal (Fig. 2C ) ganglion cells were also immunoreactive.
In other regions of the brain, many neurons immunostained with pAb-m/h-SOD1 antibody, with particularly conspicuous reactivity in large and medium-size pyramidal neurons in the cortex, as well as subsets of neurons intensively stained in hippocampus, caudoputamen, globus pallidum, substantia nigra, and thalamus. In cerebral cortex, large and medium-size pyramidal neurons showed intense SOD1 staining (Fig. 3) . As in motor neurons, particulate staining was seen throughout each perikaryon. Nonpyramidal neurons showed less immunoreactivity. The hippocampal formation showed a very distinctive distribution; neurons in sectors CA3 and CA4 of the stratum pyramidale were intensely stained for SOD1 (Fig. 3 A and B), whereas CAl neurons showed much less immunoreactivity (Fig. 3A) . Granular cells in the dentate gyrus were almost devoid of SOD1 immunoreactivity. In striatum, medium-size aspiny neurons were conspicuously immunoreactive, while other striatal neurons and the striosomal compartments were not immunostained. In thalamus, the anterodorsalis, reticularis, and ventralis nuclei exhibited prominent immunoreactive neurons. Neurons in the mitral cell layer of the olfactory bulb, pyriform cortex, amygdala complex, and red nuclei were also strongly immunostained (data not shown). In human (Fig. 2F) and nonhuman ( Fig. 3 C and D) primates the patterns of immunoreactivity in cortex, subcortical nuclei, and brainstem nuclei were similar.
Immunoelectron Microscopic Localization of SODI in Axons, Dendrites, and Perikarya of Motor Neurons. To define the subcellular distributions of SOD1 within subcompartments of motor neurons, immunoelectron microscopy was used with pAb-m/h-SOD1 antibody and silver-enhanced immunogold techniques. Immunogold particles were present in the cytosol, preferentially in the perinuclear region and euchromatic areas in the nucleus (Fig. 4A ). Mitochondria and other organelles did not stain. In motor neurons, clusters of immunogold particles were seen in the proximal portion of dendrites and in axonal compartments (Fig. 4 C and D) . In white-matter tracts of the spinal cord, clusters of immunogold particles were often identified in cross sections of myelinated axons (Fig. 4C) . Moreover, in some axons, immunogold particles were associated with membranous profiles morphologically similar to peroxisomes (Fig. 4B) , organelles previously proposed to contain SOD1 (27) . Similar subcellular patterns of SOD1 immunoreactivity were identified in other neuronal populations (e.g., pyramidal neurons in cortex and hippocampus; data not shown). Specificity of the immunogold reactivity was confirmed by the absence of immunogold particles in parallel analyses using pAb-m/h-SOD1 antibody preincubated with the immunizing peptide (data not shown).
DISCUSSION
Although SOD1 has been reported to be expressed in many different cells (1) , examination of its distribution in the human or mouse nervous system has been limited to examination in the hippocampus (5, 6, 12) and the substantia nigra [by in situ hybrydization (7)]. Only a study in canine and rat brain has disclosed the extensive presence of SOD1 in various regions of the brain (8), but study of the spinal cord has not been reported. The current effort, which takes advantage of a new, highly specific anti-peptide antibody, demonstrates not only that SOD1 is a component of several classes of neurons but also that it is selectively enriched in a subset of neurons, particularly motor neurons in spinal cord and brainstem, pyramidal neurons in sectors CA2-CA4 of hippocampus, and neurons in neocortex, pyriform cortex, and amygdala. Much of the SOD1 immunoreactivity appears to be in the cytoplasm of perikarya, dendrites, and axons, with immunoreactivity also present in nuclei and in membranous organelles, presumably peroxisomes. As immunocytochemistry is not amenable to precise quantitation, we cannot be sure as to the proportion of SOD1 in each neuronal compartment, although the highest concentration appears to be in cell bodies (Fig. 2) . However, since simple geometric considerations demonstrate that for large lumbar motor neurons in humans >99% of the cell volume is in the axon, a substantial portion of SOD1 is probably within axons.
Moreover, the presence of SOD1 in the axonal compartment strongly suggests that the enzyme is carried by anterograde transport, a conclusion further supported by accumulation of SOD1 at nerve termini (Fig. 2) . Only a few astrocytes in white matter and scattered microglial cells appear to have significant amounts of SOD1. No comparative or topographic studies on the cellular distributions of SOD1 have been previously reported, but our results are in agreement with previous biochemical and immunocytochemical studies that suggest differential expression of SOD1 in different regions of the brain (4, 8) and with studies that have focused on the presence of SOD1 mRNA or protein in discrete populations of neurons (5) (6) (7) (8) .
Our immunocytochemical findings in human and primate hippocampus show some differences from previous studies that used in situ hybridization and immunocytochemistry to report similar levels in the distribution of SOD1 mRNA and protein in all regions of the cornu Ammonis and dentate gyrus (5, 12) . We have no explanation to account for the discrepancies with previous reports. Our investigations demonstrate that neurons in the CAl sector (Sommer's sector), known to be susceptible to hypoxic/ischemic injury (28, 29) , have relatively low levels of SOD1 compared with the CA3 and CA4 sectors. It is possible that the limited amount of SOD1 in the CAl region may contribute to the susceptibility of this neuronal population to ischemic or hypoxic insults.
With regard to the mechanisms whereby mutations in SOD1 cause FALS, our findings show no evident correlations between the apparent abundance of SOD1 immunoreactivity in various neuronal populations and the vulnerabilities of neuronal degeneration in ALS. The apparent abundance of SOD1 in motor neurons of spinal cord and brainstem, as well as other subsets of nerve cells, suggests an especially important role for this enzyme in the neuroprotective pathways in these neurons. However, still unsettled is the way in which SOD1 mutations alter the activity of the enzyme to cause neuronal dysfunction and death, as some FALS-linked SOD1 mutations retain full specific activity, while others seem completely inactive (30) . Further, several lines of transgenic mice expressing the FALSassociated SOD1 mutants exhibit phenotypic and pathologic changes associated with ALS. In at least one line, the mutant enzyme is quite active (19) , with disease ensuing despite higher SOD1 levels than in wild-type mice.
As to the cascade of events leading to motor neuron death, the sum of these previous findings strongly suggests that the FALSassociated SOD1 mutations lead, at least in some cases, to aberrant enzymes with gain of adverse property(ies). Our findings here further narrow the range of possible mechanisms of motor neuron death in two additional aspects. (i) Proof that SOD1 is an abundant component in perikarya, dendrites, and axons of motor neurons strongly suggests that defects arising from SOD1 mutations act within vulnerable neurons, rather than from SOD1 deficiencies/activities in cells that interact with motor neurons. (ii) Combining the apparent abundance of SOD1 in motor neurons with our discovery that distribution of SOD1 in other neurons does not parallel vulnerability to SOD1 mutation makes it implausible that disease results from a barely adequate level of SOD1 in normal motor neurons, with FALS-associated mutations reducing SOD1 activity below a threshold necessary for motor neuron health. Rather, degeneration of neurons that apparently contain among the highest levels of SOD1 within all cell compartments is consistent with SOD1 mutations leading to aberrant, gain-of-function activities, which may be unrelated to conversion of superoxide to hydrogen peroxide. In this view, motor neurons (and other large, neurofilament-rich axons, such as the largest class of sensory neurons) may be selectively vulnerable in motor neuron disease (31) , not because SOD1 activity is limiting, but because it is so abundant.
